Year: 2008
Type: article
Abstract: Chemotherapy is mainstay treatment for cancer patients, but unfortunately many tumors are resistant to therapy.Much research now focuses on identifying mechanisms that contribute to chemoresistance.The importance of such research lies in the fact that no other treatment has proven as effective in controlling cancer metastasis and preventing tumor recurrence.This thesis focuses on: 1) identifying a cellular model appropriate for studying chemoresistance in liposarcoma and 2) understanding the role of endogenous hormones, such as prolactin (PRL) and estradiol (E2), as well as the endocrine disruptor bishpenol A (BPA), in affecting anti-cancer drug efficacy in breast cancer cells.C. Estrogen receptors…………………………………………………………. 1. Structure………………………………………………………………… 2. Splice Variants………………………………………………………….. 3. Non-classical receptors………………………………………………….a. GPR30………………………………………………………………... b.Estrogen related receptors…………………………………………….D. Estrogen signaling…………………………………………………………. 1. Genomic……………………………………………………………….... 2. Non-genomic…………………………………………………………….E. Physiological functions of estrogens………………………………………. 1. Reproduction……………………………………………………………. 2. Mammary gland development………………………………………….. Section VII.Estrogens and cancer……………………………………………….. A. Estrogen…………………………………………………………………… 1. Breast cancer…………………………………………………………….a. Estrogen and breast cancer risk………………………………………. b.ER expression in patient samples…………………………………….c.In vitro studies……………………………………………………….. d.In vivo studies………………………………………………………... 2. Other cancers…………………………………………………………… a. Endometrial………………………………………………………….. b.Prostate……………………………………………………………….c. Colon………………………………………………………………….B. Anti-estrogens……………………………………………………………... 1. Tamoxifen………………………………………………………………. 2. Aromatase Inhibitors…………………………………………………….
Author: Elizabeth W. LaPensee
Institution: University of Cincinnati
Language: English
Subfield: Endocrinology
Domain: Life Sciences
Keywords: chemoresistance, breast cancer, liposarcoma, estrogen receptor, estrogen signaling, GPR30, estrogen-related receptors, non-genomic estrogen signaling, estradiol, prolactin, bisphenol A, endocrine disruptors, antiestrogens, tamoxifen, aromatase inhibitors, endometrial cancer, prostate cancer, colon cancer, mammary gland development
Open Access status: green
Award: G8566300430
OpenAlex ID: W2257031833
